Disclosed is a pharmaceutically acceptable composition comprising: (i) 2.5% to 30% by weight levodopa carbidopa and 9% to 30% by weight arginine, wherein the composition has a pH of 8 to 10 at 25°C or (ii) 2% to 20% by weight levodopa 1% to 6% by weight carbidopa and arginine, meglumine, or both arginine and meglumine, wherein the composition has a pH of 9.1 to 9.8 at 25°C. Also disclosed is the use of the composition in treatment of a neurological or movement disorder.